Cancer Focus Fund LP, an investment fund established in collaboration with The University of Texas MD Anderson Cancer Center, is investing $4.5 million to support a first-in-human trial of Eisbach Bio GmbH’s lead candidate, EIS-12656.
Valirx plc has signed an evaluation agreement with Imperial College London enabling Valirx to evaluate research relating to novel therapeutic candidates for cancer treatment.
Aryl hydrocarbon receptor (AhR) signaling regulates gene expression in immune and skin cells and plays a critical role in maintaining skin homeostasis.
Breakpoint Therapeutics GmbH has nominated its first preclinical DNA damage response development candidate, BTX-011, for the treatment of solid tumors. IND-enabling activities have already commenced.
Unc-51-like autophagy-activating kinases 1 and 2 (ULK1/2) are enzymes that play a key role in initiating and regulating autophagy, with ULK1/2 autophagy being an adaptive stress response to multiple cancer therapies, supporting cell proliferation and tumor progression. At the recently concluded ACS meeting in New Orleans, Deciphera Pharmaceuticals LLC presented the discovery of a first-in-class ULK1/2 inhibitor as a potential new anticancer agent.
A metabolite that suppresses appetite and food intake after exercise could be the reason for the weight loss observed in patients treated with metformin to control blood glucose. A study conducted by a group of scientists at Stanford University showed how this antidiabetic drug induced the biosynthesis of N-lactoyl-phenylalanine (Lac-Phe), which has an effect reducing the body mass index.
After many years of testing different monoclonal antibodies against amyloid-β protein, the results obtained are far from being outstanding, and the control of the progression and symptoms of Alzheimer’s disease (AD) remains elusive. At the recent AD/PD 2024 conference held in Lisbon, new non-anti-amyloidogenic strategies in the starting line against AD were discussed. Professor Einar Sigurdsson from New York University gave a presentation entitled, “Single domain antibodies for therapy and diagnosis of synucleinopathies and tauopathies.”
Legochem Biosciences Inc. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, diabetes, fibrosis, obesity, liver diseases and neurological, cardiovascular and renal disorders.